Be Biopharma is looking to hire highly motivated, experienced, and innovative thinkers to join our growing team of passionate researchers to leverage B cells as a novel class of cellular medicine. This is an exciting opportunity to be part of a foundational team and help build Be Bio!
Role & Responsibilities:
- Perform research and development activities in support of AAV6 vector innovation
- Develop methods to support small scale AAV6 manufacturing for R&D use
- Develop methods to support large scale AAV6 manufacturing for pre-clinical and clinical use
- Perform up-stream and down-stream process development actives to improve yield and purity of AAV6
- Evaluate novel and emerging technologies to advance vector formulation
- Develop AAV vector analytical methods using various modern techniques (ddPCR, ACU, etc.)
- Validate AAV vector expression in B cells
- Perform collaborative interactions with internal and external collaborators
- Write and review technical documents including ELN entries, batch records, work instructions, SOPs, technical reports
- Participate in technology transfer activities to CMOs for cGMP AAV manufacturing
- Work independently in a collaborative, scientifically stimulating, fast-paced environment
Minimum Experience, Education, and Specialized Knowledge and Skills:
Must thrive in a fast-paced, growing, and innovative environment where flexibility, resourcefulness, resiliency, and communication skills are key. Excellent interpersonal skills, ability to develop important relationships with your stakeholders, and being an all around good company citizen are essential.
- D. in gene therapy vector (AAV) development or MS in Microbiology, Molecular Biology, Chemistry, Chemical Engineering, Biological Engineering or relevant biological sciences discipline
- 5+ years of Research experience in AAV
- A track record of successful research accomplishments in AAV field
- Past experience in scaling up AAV
- Excellent analytical and critical thinking
- Excellent oral and written communication skills
- Proven experience in Design of Experiment (DoE) methodology and data analysis
- Proven experience in developing novel technologies to apply to bioprocesses
About us
Be Biopharma is developing a proprietary class of engineered B cell medicines to unleash the power of cell therapies beyond cell-cell contact-dependent killing (e.g., CAR-T cells). As the centerpiece of the body’s non-contact dependent humoral immune system, B cells offer a platform for cell therapy that can secrete large amounts of diverse molecular cargo in a physiologically-regulated manner. Based on discoveries by David Rawlings, MD (Chief of Immunology, Seattle Children’s and U Washington) and Richard James, PhD (Assoc Prof of Pediatrics, Seattle Children’s and U Washington), Be Biopharma is developing a pipeline of engineered B cell medicines that can restore lost signaling, regulate disease-causing pathways, and promote defense. The company will aim to demonstrate rapid proof-of-concept in genetically-defined monogenic disease, in parallel expanding to a broader set of applications across immune disease and oncology. Be Biopharma was founded in 2020 and is supported by a syndicate of leading biotech investors.